Hebei Changshan Biochem Pharma (300255) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.021x

Based on the latest financial reports, Hebei Changshan Biochem Pharma (300255) has a cash flow conversion efficiency ratio of -0.021x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-30.86 Million ≈ $-4.52 Million USD) by net assets (CN¥1.48 Billion ≈ $216.35 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Hebei Changshan Biochem Pharma - Cash Flow Conversion Efficiency Trend (2008–2024)

This chart illustrates how Hebei Changshan Biochem Pharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Hebei Changshan Biochem Pharma (300255) financial obligations for a breakdown of total debt and financial obligations.

Hebei Changshan Biochem Pharma Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hebei Changshan Biochem Pharma ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
China Vanke Co Ltd Class A SHE:000002	-0.005x
SiteOne Landscape Supply Inc NYSE:SITE	0.098x
California Resources Corp NYSE:CRC	0.064x
United Bankshares Inc NASDAQ:UBSI	0.025x
Gerdau S.A MX:GGBN	0.053x
Clal Insurance Enterprises Holdings Ltd TA:CLIS	0.008x
Reinet Investments SCA JSE:RNI	0.000x
Olympic Circuit Technology Co Ltd SHG:603920	0.048x

Annual Cash Flow Conversion Efficiency for Hebei Changshan Biochem Pharma (2008–2024)

The table below shows the annual cash flow conversion efficiency of Hebei Changshan Biochem Pharma from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see Hebei Changshan Biochem Pharma (300255) total market value.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥1.54 Billion ≈ $224.73 Million	CN¥56.22 Million ≈ $8.23 Million	0.037x	+95.34%
2023-12-31	CN¥1.80 Billion ≈ $263.35 Million	CN¥33.73 Million ≈ $4.94 Million	0.019x	+1731.13%
2022-12-31	CN¥3.05 Billion ≈ $446.90 Million	CN¥3.13 Million ≈ $457.36K	0.001x	+9.49%
2021-12-31	CN¥3.07 Billion ≈ $449.55 Million	CN¥2.87 Million ≈ $420.19K	0.001x	+101.45%
2020-12-31	CN¥2.85 Billion ≈ $417.52 Million	CN¥-183.58 Million ≈ $-26.86 Million	-0.064x	-201.33%
2019-12-31	CN¥2.72 Billion ≈ $398.35 Million	CN¥-58.13 Million ≈ $-8.51 Million	-0.021x	-118.40%
2018-12-31	CN¥2.52 Billion ≈ $369.20 Million	CN¥292.81 Million ≈ $42.85 Million	0.116x	+74.17%
2017-12-31	CN¥2.44 Billion ≈ $356.37 Million	CN¥162.28 Million ≈ $23.75 Million	0.067x	-11.29%
2016-12-31	CN¥2.29 Billion ≈ $335.01 Million	CN¥171.96 Million ≈ $25.16 Million	0.075x	+409.43%
2015-12-31	CN¥1.57 Billion ≈ $229.92 Million	CN¥-38.14 Million ≈ $-5.58 Million	-0.024x	+59.24%
2014-12-31	CN¥1.43 Billion ≈ $208.80 Million	CN¥-84.97 Million ≈ $-12.43 Million	-0.060x	-402.15%
2013-12-31	CN¥1.29 Billion ≈ $188.11 Million	CN¥-15.24 Million ≈ $-2.23 Million	-0.012x	+81.10%
2012-12-31	CN¥1.13 Billion ≈ $164.72 Million	CN¥-70.62 Million ≈ $-10.33 Million	-0.063x	-463.52%
2011-12-31	CN¥987.45 Million ≈ $144.49 Million	CN¥17.04 Million ≈ $2.49 Million	0.017x	-87.05%
2010-12-31	CN¥219.39 Million ≈ $32.10 Million	CN¥29.25 Million ≈ $4.28 Million	0.133x	-12.34%
2009-12-31	CN¥159.19 Million ≈ $23.30 Million	CN¥24.21 Million ≈ $3.54 Million	0.152x	+146.09%
2008-12-31	CN¥93.43 Million ≈ $13.67 Million	CN¥-30.83 Million ≈ $-4.51 Million	-0.330x	--

About Hebei Changshan Biochem Pharma

SHE:300255 China Biotechnology

Market Cap

$5.56 Billion

CN¥38.01 Billion CNY

Market Cap Rank

#3342 Global

#500 in China

Share Price

CN¥41.36

Change (1 day)

+0.34%

52-Week Range

CN¥23.53 - CN¥69.80

All Time High

CN¥69.80